danaparoid

(redirected from Orgaran)

danaparoid

 [dah-nap´ah-roid]
an agent used as the sodium salt in prophylaxis of pulmonary thromboembolism and deep venous thrombosis.

danaparoid

/da·nap·a·roid/ (dah-nap´ah-roid) an antithrombotic used as the sodium salt in the prophylaxis of pulmonary thromboembolism and deep venous thrombosis.

danaparoid

an anticoagulant.
indications It is used to prevent vein thrombosis in hemodialysis, stroke, elective surgery for malignancy or total hip replacement, and hip fracture surgery.
contraindications Hypersensitivity to this drug, sulfites, or pork products prohibits its use. Other factors that contraindicate its use include hemophilia, leukemia with bleeding, thrombocytopenia, purpura, cerebrovascular hemorrhage, cerebral aneurysm, severe hypertension, and other severe cardiac disease.
adverse effects Life-threatening side effects include hemorrhage and thrombocytopenia. Hypersensitivity reactions and rash are additional adverse effects.

danaparoid

Orgaran® Cardiovascular disease An injectable, LMW heparin that ↓ risk of postop DVT and PE after hip replacement surgery; it is also used for heparin-induced thrombocytopenia. See Deep vein thrombosis, Heparin-induced thrombocytopenia, Pulmonary embolism.
References in periodicals archive ?
6 mL; Orgaran, Schering-Plough Corporation, Kenilworth, New Jersey) did not require additional preparation.
Common pharmacologicals used in DVT prophylaxis include Innohep, Orgaran and Clexane (New Ethicals Compendium 2004).
Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org10172).
Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia.